Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||27 Jun 2017||Lorem|
|TG Therapeutics’ GENUINE CLL trial data supportive of accelerated approval despite protocol amendment concerns – experts||28 Mar 2017||Alaric DeArment|
|AbbVie/Roche's Venclexta has solid backing for Rituxan combination in CLL, positive Phase III trial – experts||17 Mar 2017||Alaric DeArment|
|AstraZeneca’s durvalumab/tremelimumab Phase III NSCLC dosing regimen should boost safety profile though toxicity caution remains - experts||16 Feb 2017||Hamish McDougall|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer